Informations générales (source: ClinicalTrials.gov)
Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE)
Interventional
N/A
Institut Curie (Voir sur ClinicalTrials)
janvier 2017
janvier 2032
12 septembre 2025
SCANDARE is a prospective biobanking study on tumor (+/- nodes), plasma and blood samples
at different time points in ovarian, triple negative breast, Head and Neck Cancer,
advanced stage treatment-naïve cervical cancer and sarcoma (breast angiosarcoma and
uterine sarcoma) cancers. This study will allowed to identify new molecular and/or
immunological biomarkers associated with clinical and biological features of the tumors.
All patients will receive standard treatment according to the stage of the diseases and
usual procédures.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT CURIE | 10/04/2025 13:12:19 | Contacter | |||
| CLCC RENE HUGUENIN INSTITUT CURIE | 10/04/2025 13:12:03 | Contacter | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Centre Leon Berard - 69373 - Lyon - France | Nicolas CHOPIN, MD | Contact (sur clinicalTrials) | |||
| Centre Oscar Lambret - 59000 - Lille - France | Camille PASQUESOONE, MD | Contact (sur clinicalTrials) | |||
| Institut Bergonie - 33076 - Bordeaux - France | Adeline PETIT, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
1. Tumor types :
1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or
neoadjuvant chemotherapy
2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible
for surgery or neoadjuvant chemotherapy
3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for
surgery
4. Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1
with nodal metastasis, postoperative positive margin or parametrial-vaginal
involvement, and (2) stage ≥IIa2).
5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma
or (2) uterine sarcoma eligible for surgery or systemic treatment
2. Male or female patients ≥ 18 years of age
3. Signed informed consent
1. Tumor types :
1. Newly diagnosed treatment-naïve ovarian cancer patients eligible for surgery or
neoadjuvant chemotherapy
2. Newly diagnosed treatment-naïve triple-negative breast cancer patients eligible
for surgery or neoadjuvant chemotherapy
3. Newly diagnosed treatment-naïve head and neck cancer patients eligible for
surgery
4. Newly diagnosed treatment-naïve cervical cancer patients (1) stage Ia - IIa1
with nodal metastasis, postoperative positive margin or parametrial-vaginal
involvement, and (2) stage ≥IIa2).
5. Newly diagnosed treatment-naïve sarcoma cancer patients (1) breast angiosarcoma
or (2) uterine sarcoma eligible for surgery or systemic treatment
2. Male or female patients ≥ 18 years of age
3. Signed informed consent
1. Male or female patients ≤18 years old
2. Patients with any psychological, familial, sociological or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule
3. Individually deprived of liberty or placed under the authority of a tutor
4. Patients not affiliated to the Social Security System